Anjarium Biosciences raises CHF 55.5 million in series A financing round
Anjarium Biosciences, a Swiss biotech company, recently closed a CHF 55.5 million (USD 61 million) Series A financing round, co-led by Gimv and Abingworth. The fundraising also saw significant participation from Omega Funds, Pfizer Ventures and surveyor capital (a citadel company).
The proceeds from the series A financing will enable Anjarium to expand its team, develop its platform, and push serval therapeutic pipeline programs towards clinical trials. Anjarium is focused on creating a new class of non-viral gene therapies to deliver more predictable, enduring, and inclusionary ways to tackle genetic disease throughout a patient’s lifetime.
The advisors
Baker McKenzie advised the consortium of VC funds in all legal aspects of the closing of the financing round. The team was led by partner Martin Frey (pictured top) and associate Kevin Ardüser (both Zurich based, coporate /m&a).
Vischer advised Anjarium Biosciences with a team composed of partner Matthias Staehelin (pictured left) and associate Pauline Pfirter (both coporate /m&a).
